{"id":"W2947218961","doi":"10.1200/jco.2019.37.15_suppl.5519","title":"Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Carboplatin; Common Terminology Criteria for Adverse Events; Pembrolizumab; Internal medicine; Ovarian cancer; Tolerability; Neutropenia; Adverse effect; Fallopian tube cancer; Oncology; Topotecan; Bevacizumab; Gastroenterology; Progression-free survival; Surgery; Cancer; Chemotherapy; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004019257,0.0009682876,0.0009932271,0.0003416235,0.0004523307,0.001060462,0.0007762508,0.001054116,0.004706167],"category_scores_gemma":[0.001527167,0.000382113,0.001727738,0.0003265251,0.000250946,0.0005607979,0.0004916865,0.001692359,0.00161013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00109098,"about_ca_system_score_gemma":0.001383905,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001262132,"about_ca_topic_score_gemma":0.003023986,"domain_scores_codex":[0.9991108,0.0003872273,0.00007179035,0.00008798086,0.0001235088,0.0002186531],"domain_scores_gemma":[0.9990143,0.0001619208,0.0002361429,0.00008871149,0.0001132614,0.0003856436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4675528,0.01811121,0.03681413,0.002901528,0.007433533,0.001223284,0.0003138271,0.004686974,0.02625466,0.0007505886,0.08110675,0.3528507],"study_design_scores_gemma":[0.3275832,0.3396687,0.1971025,0.0007721641,0.007544688,0.003978267,0.0001321626,0.004262399,0.01697493,0.0009228169,0.1009656,0.00009263783],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8551363,0.03490623,0.004516756,0.005924341,0.00151926,0.01505454,0.03812645,0.0007639195,0.0440523],"genre_scores_gemma":[0.9002841,0.006626987,0.006982731,0.00540617,0.0007030216,0.007521311,0.05546376,0.0001815851,0.01683023],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004706167,"threshold_uncertainty_score":0.02125615,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07024901414033385,"score_gpt":0.4214427881275677,"score_spread":0.3511937739872339,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}